Lymphoma is a broad term for cancer that begins in cells of the lymph system. It includes the lymph nodes, spleen, thymus gland and bone marrow. Lymphoma affects the body’s lymph system (also known as the lymphatic system). Nearly 30,000 new cases of diffuse large B-cell lymphoma are diagnosed annually in the U.S. The term “refractory” is used to describe when the lymphoma does not respond to treatment. Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone is the current used in the treatment of relapsed or refractory diffuse large b-cell lymphoma.
Request Free Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/4426
High prevalence of lymphoma is expected to propel growth of the global relapsed or refractory diffuse large B-cell lymphoma market over the forecast period. For instance, according to Leukemia and Lymphoma Society, 176,200 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019.
Covid-19 Impact Analysis
Globally, as of 4:14pm CET, 29 December 2021, there have been 281,808,270 confirmed cases of COVID-19, including 5,411,759 deaths, reported to WHO. As of 3 January 2022, a total of 8,693,832,171 vaccine doses have been administered. Patients with lymphoma have an increased susceptibility to infection with SARS-CoV-2. According to a study published in March 2021 in the journal Hemasphere, pooled risk of death for lymphomas was 32% in a meta-analysis of hematologic malignancies and COVID-19 that incorporated data from more than 3000 patients.
Key Takeaways
Major players operating in the global relapsed or refractory diffuse large B-cell lymphoma market are focused on R&D to expand their product portfolio. For instance, in December 2021, MorphoSys US Inc. and Incyte announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab (Monjuvi) in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Competitive Landscape:
Major players operating in the global relapsed or refractory diffuse large B-cell lymphoma market include, Bristol Myers Squibb, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Karyopharm Therapeutics, MorphoSys US Inc., Merck & Co., Inc., and Novartis AG.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4426
Reasons to Buy this Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Relapsed or Refractory Diffuse Large B-cell Lymphoma market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Relapsed or Refractory Diffuse Large B-cell Lymphoma market
➡Leading company profiles reveal details of key Relapsed or Refractory Diffuse Large B-cell Lymphoma market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Relapsed or Refractory Diffuse Large B-cell Lymphoma market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Buy This Complete Business Report With Flat 30% Off @ https://www.coherentmarketinsights.com/insight/buy-now/4426
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- PEST Analysis
- Market Dynamics
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Safety Syringes for COIVD-19 Vaccines
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Drug Type, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Monjuvi
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- XPOVIO
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Polivy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Kymriah
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Yescarta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Introduction
- Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market, By Region, 2017 – 2028, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 – 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- MorphoSys US Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol Myers Squibb
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Karyopharm Therapeutics
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Hoffmann-La Roche AG
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Gilead Sciences, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- MorphoSys US Inc.
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837